InsidersTradesSigma
Track the Iradimed CORP stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Iradimed CORP has published 200 insider filings. Market capitalisation: €1.2bn. The latest transaction was disclosed on 23 June 2026 (Levée d'options). Among the most active insiders: Susi Roger E.. Every trade is free.
200
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€38m
149 ops.
Sell Volume
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,050 of 29,062 companies
60.9
score / 100
Value32
Quality89
FCF yld1.5%
Earn yld2.0%
EV/EBITDA40.8x
ROE24%
Gross mgn77%
Net mgn27%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 June 2026
Declarations200 total
5,796 sharesCommon StockSEC:0001253497-26-000005:0
2,319 sharesCommon StockSEC:0001253497-26-000005:1
2,819 shares@ US$88.980.019% mcap0.7% of flowCommon StockSEC:0001613801-26-000028:0
931 shares@ US$89.700.0063% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:1
998 shares@ US$84.130.0063% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:2
847 shares@ US$85.770.0055% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:3
742 shares@ US$86.520.0048% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:4
900 shares@ US$88.000.0060% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:5
263 shares@ US$88.810.0018% mcap0.1% of flowCommon StockSEC:0001613801-26-000028:6
3,580 shares@ US$93.140.025% mcap0.9% of flowCommon StockSEC:0001613801-26-000026:0
1,420 shares@ US$93.900.0100% mcap0.3% of flowCommon StockSEC:0001613801-26-000026:1
1,162 shares@ US$89.730.0078% mcap0.3% of flowCommon StockSEC:0001613801-26-000026:2
140 shares@ US$90.600.0010% mcap0.0% of flowCommon StockSEC:0001613801-26-000026:3
606 shares@ US$91.650.0042% mcap0.1% of flowCommon StockSEC:0001613801-26-000026:4
592 shares@ US$92.660.0041% mcap0.1% of flowCommon StockSEC:0001613801-26-000026:5
1,847 shares@ US$91.840.013% mcap0.4% of flowCommon StockSEC:0001613801-26-000024:0
2,564 shares@ US$92.790.018% mcap0.6% of flowCommon StockSEC:0001613801-26-000024:1
589 shares@ US$93.450.0041% mcap0.1% of flowCommon StockSEC:0001613801-26-000024:2
2,107 shares@ US$93.710.015% mcap0.5% of flowCommon StockSEC:0001613801-26-000024:3
393 shares@ US$94.550.0028% mcap0.1% of flowCommon StockSEC:0001613801-26-000024:4
982 shares@ US$95.580.2% of flowCommon StockSEC:0001613801-26-000022:4
1,357 shares@ US$95.210.3% of flowCommon StockSEC:0001613801-26-000022:0
3,074 shares@ US$96.240.8% of flowCommon StockSEC:0001613801-26-000022:1
569 shares@ US$96.780.1% of flowCommon StockSEC:0001613801-26-000022:2
1,518 shares@ US$94.360.4% of flowCommon StockSEC:0001613801-26-000022:3
25 of 200 declarations
关于 Iradimed CORP
IRADIMED CORP.（股票代码：IRMD）是一家在美国纳斯达克市场上市的美国医疗设备公司。该公司在医疗设备的一个高度专业化领域运营：它设计、制造、销售和分销MRI兼容的医疗设备，以及相关的配件、耗材和服务。其业务专注于医院和护理环境中对安全性要求高的应用，即患者在MRI检查过程中必须接受输液治疗和生命体征监测，而在此环境中，传统设备可能带来安全和操作挑战。([static1.squarespace.com](https://static1.squarespace.com/static/640779294f16ad6e3bf57fc8/t/6781a843facb34455f60e189/1736550467421/IRMD%2BPR%2B-%2BPreliminary%2BQ4%2B2024%2BRevenue%2Bfor%2BJPM%2B%28KLG%2BComments%29-508881756-v2.pdf)) IRADIMED的历史可追溯到1992年，当时它在俄克拉荷马州注册成立为IRI Development, Inc.。公司后来于2014年4月重组为特拉华州公司。其创始人Roger Susi在MRI患者监测领域拥有悠久的运营历史；他于1979年创立了Invivo Research，并协助开发了第一个MRI兼容的患者监测系统。这一历史渊源很重要，因为它表明IRADIMED是一家围绕MRI安全患者护理领域数十年专业知识而建立的技术公司。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm)) 产品组合围绕扫描室的四项核心产品：MRidium 3870 MRI兼容静脉输液泵系统、MRidium 3860+ MRI兼容静脉输液泵系统、3880 MRI兼容患者生命体征监测系统以及带RALU FMD的3600 FMD。公司强调其泵是非磁性的，设计用于0.2T至3T的磁场，并配备了药物库、警报和可充电电池操作等临床功能。管理层还表示，IRADIMED在MRI兼容静脉输液泵领域目前没有直接竞争对手，这支持了其可防御的利基市场地位。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm)) 在商业方面，公司通过美国直销团队和国际分销商网络进行销售。虽然其传统市场是MRI部门，但IRADIMED正在将业务扩展到重症监护室、急诊室和其他重症护理环境，以扩大MRI兼容设备在医院中的应用。公司总部和主要制造业务现位于佛罗里达州奥兰多，在一个专门建造的约62,300平方英尺的设施中，该设施完全由现金资助。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm)) 近期发展具有建设性。2025年，IRADIMED推出了下一代MRidium 3870泵，管理层表示这将支持2026年及以后的增长。公司还增加了股东回报，在2025年12月宣布每股0.50美元的特别现金股息后，于2026年2月将其常规季度股息提高至每股0.20美元。在其2026年展望中，管理层预计收入为91 million至96 million美元，表明需求持续增长和运营纪律。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm))
